Imaging mass cytometry distinguished tumor microenvironment patterns between metastatic and nonmetastatic cutaneous squamous cell carcinoma in solid organ transplant recipients, according to a short communication published in the October 2026 issue of the Journal of Investigative Dermatology.

The study appears in Volume 146, Issue 10, pages 2924-2928.e10, under a Creative Commons open-access license (DOI 10.1016/j.jid.2026.04.020). It carries the title "Spatial immune profiling characterizes tumor microenvironment heterogeneity between metastatic and nonmetastatic cutaneous squamous cell carcinoma in organ transplant patients."

What did the investigators set out to compare?

First author Veerle A. Merkus and colleagues stratified cSCC specimens from sOTR into two outcome-defined cohorts:

• cSCC-M: cSCC that metastasized
• cSCC-nonM: cSCC that did not metastasize

Cutaneous squamous cell carcinoma is the most common malignancy in solid organ transplant recipients, who require lifelong pharmacologic immunosuppression. Metastasis, though uncommon overall, accounts for the majority of cSCC-specific mortality in this group. Tools that distinguish aggressive from indolent cSCC at the time of biopsy would inform surveillance imaging frequency, sentinel lymph node workup, and adjuvant therapy referral.

Why imaging mass cytometry?

Imaging mass cytometry uses metal-tagged antibodies detected by mass spectrometry after laser ablation of a tissue section. The platform resolves more than 30 markers simultaneously while preserving the original two-dimensional tissue architecture, sidestepping the spectral overlap that limits conventional multiplex immunofluorescence. That combination suits comparing tumor-immune interfaces across cSCC specimens, where dendritic cell (DC) positioning, T-cell infiltration, and stromal architecture may diverge between outcomes.

What does spatial analysis add to standard profiling?

Bulk sequencing and flow cytometry measure average immune composition but discard geographic information. In cSCC, immune evasion often involves physical exclusion of cytotoxic T cells from the tumor core, a pattern that coordinate-preserving readouts can capture but disaggregated assays cannot. Spatial analyses quantify cell-cell distances, neighborhood cell-type composition, and peritumoral versus intratumoral localization, features that may carry prognostic weight independent of bulk T-cell counts.

Which immune compartments were of interest?

The study's keyword set — cSCC, imaging mass cytometry, organ transplant patients, spatial analyses, tumor microenvironment — frames the analysis around cellular constituents of the TME. The abbreviation list defines DCs (dendritic cells) explicitly and codifies the two outcome groups (cSCC-M, cSCC-nonM) and the recipient population (sOTR).

Why publish as a Letter to the Editor?

JID's "Letters to the Editor" track accommodates short-format reports that communicate focused mechanistic findings without the full Introduction-Methods-Results-Discussion structure of an original article. The format suits targeted single-cohort comparisons such as the cSCC-M versus cSCC-nonM design here, where the experimental core is one well-defined platform applied to two clinically defined groups.

What is the field's next step?

The communication joins a growing body of spatial proteomics applied to keratinocyte carcinoma, complementing single-cell RNA-sequencing efforts that sacrifice tissue context for cellular resolution. Independent replication in larger sOTR cohorts, ideally with prospective enrollment and clinical follow-up, will determine whether the TME patterns reported here can be operationalized as a clinically actionable risk-stratification biomarker. The Creative Commons license should lower access barriers for transplant dermatology programs seeking to validate the approach on local biobanks.